SCHEMBL6070180

SCHEMBL6070180

COC(=O)c1cccc(Nc2nnc(-c3cccc(C#N)c3)s2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 1/20 0.49
PLAU P00749 1/20 0.45
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
ROCK1 Q13464 2/20 0.44
ROCK2 O75116 1/20 0.44
PDE5A O76074 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ABL1 P00519 1/20 0.42
BCR P11274 1/20 0.42
SRC P12931 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 2/20 0.42
TP53 P04637 1/20 0.42
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
CYP1A1 P04798 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP1B1 Q16678 1/20 0.41
WNT3A P56704 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23553638 0.81 CYP1A2 (0.61) PLAUNPC1RAB9AALDH1A1LMNA
SCHEMBL5928256 0.80 RAB9A (0.52) PLAUNPC1RAB9AROCK1ALDH1A1
SCHEMBL6153541 0.80 ROCK2 (0.56) RAB9AROCK1ROCK2ALDH1A1LMNA
SCHEMBL6154361 0.80 KDM4E (0.60) NPC1RAB9AROCK1ROCK2HSD17B10
SCHEMBL7822720 0.77 PLAU (0.61) PLAU
SCHEMBL14090389 0.76 CCNC (0.49) NPC1RAB9AROCK1ROCK2HSD17B10
SCHEMBL6070447 0.76 CSNK2A2 (0.50) NPC1RAB9AROCK1PDE5AHSD17B10
SCHEMBL4954816 0.76 GUSB (0.56) BLMNPC1RAB9AROCK1ROCK2
SCHEMBL60040 0.74 MRGPRX4 (0.56) PLAURAB9ATP53TSHR
SCHEMBL30444713 0.74 MRGPRX4 (0.56) PLAURAB9ATP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7122565-B2 Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors WARNER-LAMBERT LLC (US) 2006-10-17 US disclosed
EP-1326853-B1 THIADIAZOLES AND OXADIAZOLES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS WARNER LAMBERT CO (US) 2005-09-07 EP disclosed
EP-1326853-A1 NEW THIADIAZOLES AND OXADIAZOLES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS Warner-Lambert Company LLC (US) 2003-07-16 EP disclosed
US-20030045557-A1 Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors WARNER-LAMBERT COMPANY 2003-03-06 US disclosed
WO-2002028847-A1 NEW THIADIAZOLES AND OXADIAZOLES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045557-A1 Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors PDE3A, PDE3B, PDE7A BLM 1111/4885PLAU 2325/4885NPC1 4586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.